Literature DB >> 18287023

A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.

Guofeng Cheng1, Ana Montero, Pablo Gastaminza, Christina Whitten-Bauer, Stefan F Wieland, Masanori Isogawa, Brenda Fredericksen, Suganya Selvarajah, Philippe A Gallay, M Reza Ghadiri, Francis V Chisari.   

Abstract

An amphipathic alpha-helical peptide (C5A) derived from the membrane anchor domain of the hepatitis C virus (HCV) NS5A protein is virocidal for HCV at submicromolar concentrations in vitro. C5A prevents de novo HCV infection and suppresses ongoing infection by inactivating both extra- and intracellular infectious particles, and it is nontoxic in vitro and in vivo at doses at least 100-fold higher than required for antiviral activity. Mutational analysis indicates that C5A's amphipathic alpha-helical structure is necessary but not sufficient for its virocidal activity, which depends on its amino acid composition but not its primary sequence or chirality. In addition to HCV, C5A inhibits infection by selected flaviviruses, paramyxoviruses, and HIV. These results suggest a model in which C5A destabilizes viral membranes based on their lipid composition, offering a unique therapeutic approach to HCV and other viral infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287023      PMCID: PMC2268589          DOI: 10.1073/pnas.0712380105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.

Authors:  Jan Münch; Ludger Ständker; Knut Adermann; Axel Schulz; Michael Schindler; Raghavan Chinnadurai; Stefan Pöhlmann; Chawaree Chaipan; Thorsten Biet; Thomas Peters; Bernd Meyer; Dennis Wilhelm; Hong Lu; Weiguo Jing; Shibo Jiang; Wolf-Georg Forssmann; Frank Kirchhoff
Journal:  Cell       Date:  2007-04-20       Impact factor: 41.582

2.  In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

Authors:  Chao Lin; Cynthia A Gates; B Govinda Rao; Debra L Brennan; John R Fulghum; Yu-Ping Luong; J Daniel Frantz; Kai Lin; Sue Ma; Yun-Yi Wei; Robert B Perni; Ann D Kwong
Journal:  J Biol Chem       Date:  2005-08-08       Impact factor: 5.157

3.  Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication.

Authors:  Lieven J Stuyver; Tamara R McBrayer; Phillip M Tharnish; Jeremy Clark; Laurent Hollecker; Stefania Lostia; Tammy Nachman; Jason Grier; Matthew A Bennett; Meng-Yu Xie; Raymond F Schinazi; John D Morrey; Justin L Julander; Phillip A Furman; Michael J Otto
Journal:  Antivir Chem Chemother       Date:  2006

4.  Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles.

Authors:  Pablo Gastaminza; Sharookh B Kapadia; Francis V Chisari
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

5.  Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells.

Authors:  Bruno Sainz; Francis V Chisari
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

6.  Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells.

Authors:  Jeremy C Jones; Elizabeth A Turpin; Hermann Bultmann; Curtis R Brandt; Stacey Schultz-Cherry
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

7.  NMR structure and molecular dynamics of the in-plane membrane anchor of nonstructural protein 5A from bovine viral diarrhea virus.

Authors:  Nicolas Sapay; Roland Montserret; Christophe Chipot; Volker Brass; Darius Moradpour; Gilbert Deléage; François Penin
Journal:  Biochemistry       Date:  2006-02-21       Impact factor: 3.162

8.  Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein.

Authors:  Luyun Huang; Jungwook Hwang; Suresh D Sharma; Michele R S Hargittai; Yingfeng Chen; Jamie J Arnold; Kevin D Raney; Craig E Cameron
Journal:  J Biol Chem       Date:  2005-08-25       Impact factor: 5.157

9.  Exosomes and HIV Gag bud from endosome-like domains of the T cell plasma membrane.

Authors:  Amy M Booth; Yi Fang; Jonathan K Fallon; Jr-Ming Yang; James E K Hildreth; Stephen J Gould
Journal:  J Cell Biol       Date:  2006-03-13       Impact factor: 10.539

10.  A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3.

Authors:  M K Pastey; T L Gower; P W Spearman; J E Crowe; B S Graham
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

View more
  62 in total

1.  A human claudin-1-derived peptide inhibits hepatitis C virus entry.

Authors:  Youhui Si; Shufeng Liu; Xiuying Liu; Jana L Jacobs; Min Cheng; Yuqiang Niu; Qi Jin; Tianyi Wang; Wei Yang
Journal:  Hepatology       Date:  2012-06-11       Impact factor: 17.425

Review 2.  Mixing the right hepatitis C inhibitor cocktail.

Authors:  Michael A Gelman; Jeffrey S Glenn
Journal:  Trends Mol Med       Date:  2010-11-23       Impact factor: 11.951

3.  Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics.

Authors:  Jinjin Zhang; Jered C Garrison; Larisa Y Poluektova; Tatiana K Bronich; Natalia A Osna
Journal:  Biomaterials       Date:  2015-08-08       Impact factor: 12.479

4.  The rigid amphipathic fusion inhibitor dUY11 acts through photosensitization of viruses.

Authors:  Frederic Vigant; Axel Hollmann; Jihye Lee; Nuno C Santos; Michael E Jung; Benhur Lee
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

5.  A broad-spectrum antiviral targeting entry of enveloped viruses.

Authors:  Mike C Wolf; Alexander N Freiberg; Tinghu Zhang; Zeynep Akyol-Ataman; Andrew Grock; Patrick W Hong; Jianrong Li; Natalya F Watson; Angela Q Fang; Hector C Aguilar; Matteo Porotto; Anna N Honko; Robert Damoiseaux; John P Miller; Sara E Woodson; Steven Chantasirivisal; Vanessa Fontanes; Oscar A Negrete; Paul Krogstad; Asim Dasgupta; Anne Moscona; Lisa E Hensley; Sean P Whelan; Kym F Faull; Michael R Holbrook; Michael E Jung; Benhur Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-28       Impact factor: 11.205

Review 6.  Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.

Authors:  Ali Sabahi; Susan L Uprichard; William C Wimley; Srikanta Dash; Robert F Garry
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

Review 7.  Entangled in a membranous web: ER and lipid droplet reorganization during hepatitis C virus infection.

Authors:  Nathan L Meyers; Krystal A Fontaine; G Renuka Kumar; Melanie Ott
Journal:  Curr Opin Cell Biol       Date:  2016-05-27       Impact factor: 8.382

8.  Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities.

Authors:  Richard Maskiewicz; Michael Bobardt; Udayan Chatterji; Simi Gunaseelan; Charlene S Dezzutti; Francois Penin; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

9.  Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.

Authors:  Ana M Chamoun-Emanuelli; Michael Bobardt; Bernard Moncla; Marie K Mankowski; Roger G Ptak; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

10.  A p7 Ion Channel-derived Peptide Inhibits Hepatitis C Virus Infection in Vitro.

Authors:  Wei Hong; Yange Lang; Tian Li; Zhengyang Zeng; Yu Song; Yingliang Wu; Wenxin Li; Zhijian Cao
Journal:  J Biol Chem       Date:  2015-08-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.